By Judy George
Source Medpagetoday
The FDA approved an oral extended-release formulation of levodopa and carbidopa known as IPX203 (Crexont) to treat Parkinson’s disease, Amneal Pharmaceuticals announcedopens in a new tab or window Wednesday.
The treatment is a novel formulation that combines immediate-release granules of carbidopa and levodopa with extended-release pellets of levodopa. Its design means that therapeutic levels of levodopa and carbidopa may be maintained with less frequent dosing to maximize “good on” time, defined as time without troublesome dyskinesia.
Read more https://www.medpagetoday.com/neurology/parkinsonsdisease/111436